Hamilton Locke advised Tryptamine Therapeutics Limited on the deal. Tryptamine Therapeutics Limited secured the acquisition and backdoor listing of Tryp Therapeutics Inc., a biotechnology entity previously...
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here